All In Biotech

NDA 021999 · Janssen Pharms

Invega

Paliperidone · Oral · Atypical Antipsychotic

Novel

Last checked: Nov 20, 2026Latest source record: Jan 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Dec 19, 2006

Approved uses

5

Original approval plus efficacy supplements

Registered trials

186

60 Phase 3, 3 recruiting

FAERS reports

23,466

11,599 serious, 845 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning . Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Jan 31, 2025.

INVEGA is an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1.1 ) Adults: Efficacy was established in three 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 12–17): Efficacy was established in one 6-week trial. ( 14.1 ) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. ( 1.2 ) Efficacy was established in two 6-week trials in adult patients. ( 14.2 ) 1.1 Schizophrenia INVEGA (paliperidone) Extended-Release Tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14.1) ] . The efficacy of INVEGA in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. 1.2 Schizoaffective Disorder INVEGA (paliperidone) Extended-Release Tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14.2) ] . The efficacy of INVEGA in schizoaffective disorder was established in two 6-week trials in adults.

Mechanism: Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone in schizophrenia is unclear. However, the drug's therapeutic effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2A ) receptor antagonism.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • INVEGA · PALIPERIDONE 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued
  • INVEGA · PALIPERIDONE 6MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INVEGA · PALIPERIDONE 9MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INVEGA · PALIPERIDONE 3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • INVEGA · PALIPERIDONE 1.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Paliperidone" as an intervention, any sponsor and status, largest first.

All 186 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injury4,330
  • gynaecomastia3,666
  • drug ineffective1,795
  • abnormal weight gain1,662
  • off label use1,565
  • weight increased1,390
  • hyperprolactinaemia1,272
  • galactorrhoea1,060
  • sedation762
  • dyskinesia717
  • dystonia715
  • treatment noncompliance684

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2007696
2008743
2009650
2010524
2011687
2012783
2013652
2014966
20152,359
20164,208
20173,453
2018910
2019847
2020814
2021812
2022932
2023924
2024801
20251,024
2026681

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Invega (Paliperidone)

2024 spending

$2.3M

Beneficiaries

704

4,179 claims

Per beneficiary

$3,336

$13.75 per unit

View as table
YearSpending
2020$122,657,282
2021$84,143,307
2022$25,750,207
2023$5,169,576
2024$2,348,551

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 332 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.